Joseph Grisanti
Orchard Park, NYNPI 1093825721
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $599,802 of the $819,418 with a category attached, or 73.2%. 29 manufacturers reported payments, led by Amgen at 44.7% of the total. Reporting peaked in 2019 at $231,155 and has fallen 84.7% since, to $35,379 in 2025.
Across 1,155 payments — averaging $709.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$366K
- Boehringer Ingelheim$106K
- Janssen Scientific Affairs, LLC$92K
- AstraZeneca$60K
- United Rheumatology$36K
- GSK$34K
- plus $125K from 23 others
Across 85 payments — averaging $4587.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$123K
- Novartis$106K
- AbbVie$71K
- Amgen$40K
- Janssen Research & Development, LLC$36K
- Sanofi US Services Inc.$8K
- plus $5K from 1 others
What the payments were for
- Consulting fees$86,81211%
- Speaking & faculty fees$599,80273%
- Travel & lodging$106,24213%
- Food & beverage$26,2273%
- Education$3350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 463 | $366,266 |
| Boehringer Ingelheim | 67 | $105,642 |
| Janssen Scientific Affairs, LLC | 76 | $92,291 |
| AstraZeneca(2 entities) | 68 | $59,728 |
| United Rheumatology | 5 | $36,250 |
| GSK | 34 | $34,361 |
| UCB, Inc. | 48 | $27,072 |
| Novartis | 48 | $24,296 |
| Johnson & Johnson | 90 | $22,930 |
| Aurinia Pharma U.S., Inc. | 26 | $16,844 |
| Sanofi | 24 | $14,419 |
| Lilly USA, LLC | 23 | $7,159 |
| Gilead | 14 | $5,471 |
| Regeneron Healthcare Solutions, Inc. | 17 | $4,485 |
| Pfizer | 61 | $609 |
| AbbVie | 27 | $483 |
| Genentech USA, Inc. | 23 | $337 |
| E.r. Squibb & Sons, L.L.C. | 15 | $244 |
| Sanofi-aventis U.S. LLC | 5 | $136 |
| Bristol Myers Squibb | 4 | $70 |
| Daiichi Sankyo Inc. | 4 | $68 |
| US Oncology Corporate, Inc. | 2 | $63 |
| Pacira Therapeutics, Inc. | 3 | $47 |
| Grifols USA, LLC | 2 | $45 |
| Actelion Pharmaceuticals US, Inc. | 2 | $28 |
| Sanofi Pasteur Inc. | 1 | $24 |
| Octapharma USA, Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 22 | $210,749 |
| Xeljanz XrTofacitinib Citrate | 19 | $152,662 |
| EnbrelEtanercept | 19 | $136,108 |
| KevzaraSarilumab | 12 | $54,721 |
| MethotrexateMethotrexate Sodium | 115 | $3,589 |
| Allopurinol | 142 | $3,160 |
| Colchicine | 38 | $2,625 |
| Mycophenolic AcidMycophenolate Sodium | 12 | $2,191 |
| Hydroxychloroquine Sulfate | 37 | $2,021 |
| Duloxetine Hcl | 26 | $741 |
| Celecoxib | 13 | $583 |
| Leucovorin Calcium | 16 | $561 |
| Prednisone | 33 | $413 |
| Gabapentin | 15 | $300 |
| Diclofenac Sodium | 14 | $261 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel | $366,266 | $136,10819 claims |
| SanofiKevzara | $14,419 | $54,72112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in New Yorkon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.